Perspectum
PrivateLast Round
Grant
Nov 14, 2024
Total Funding Raised
$111.63M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Perspectum operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was a Grant round in November 2024.
Perspectum is a healthtech company that provides AI-driven medical imaging software and non-invasive diagnostic solutions for patients with liver disease, diabetes, and cancer.
Sector
Healthcare & Life Sciences
Verticals
Medical Imaging, Medical AI, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Usage-Based SaaS, Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Perspectum Comparables
Compare Perspectum with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Resonance Health Ltd | 82% | |
| Quibim | 79% | |
| Echosens | 75% |
For institutional investors. Book with your work email.
Perspectum Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 14, 2024 | ||||
| Series C | Mar 15, 2023 | ||||
| IPO | Aug 6, 2021 | ||||
| Series B | Apr 14, 2020 | ||||
| Grant | Apr 16, 2019 | ||||
Grant | Jan 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Perspectum Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Barclays PLC | IPO |
| Eureka Network | Grant |
| Oxford Science Enterprises | Series B |
| Westgrove Partners | Series B |
| British Patient Capital | Series C |
| University of Oxford | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 35% MoM, from 10.9K to 14.7K.
- Mar 4, 2026
Maintains ISO 13485 and EU MDR certifications for SaMD products.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 6, 2026
Perspectum hires Warren Cresswell as Chief Executive Officer at its precision health company in the United Kingdom on Oct 6th '26.
For institutional investors. Book with your work email.
Perspectum Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Perspectum's valuation, stock price, and market status.
Is Perspectum a public or private company?
Perspectum is a private company.
What is the current stock price of Perspectum?
Perspectum is a private company, so its shares have no public market price. Caplight tracks Perspectum's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Perspectum worth (valuation)?
Valuation information for Perspectum is not publicly available.
Can I buy Perspectum stock?
Perspectum shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Perspectum's last funding round?
Perspectum's most recent funding round was Grant on November 14, 2024.
Who are the main investors in Perspectum?
Key investors in Perspectum include Barclays PLC, Eureka Network, Innovate UK, Oppenheimer & Co. Inc., Food and Drug Administration.
Will Perspectum IPO soon?
No public IPO plans have been announced for Perspectum.
How can I track Perspectum secondary market activity?
Caplight tracks bids, offers, and trades in Perspectum's shares on secondary markets.